Last reviewed · How we verify
Pascoflair
At a glance
| Generic name | Pascoflair |
|---|---|
| Sponsor | Pascoe Pharmazeutische Praeparate GmbH |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®
- Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety (PHASE4)
- Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST) (PHASE3)
- Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pascoflair CI brief — competitive landscape report
- Pascoflair updates RSS · CI watch RSS
- Pascoe Pharmazeutische Praeparate GmbH portfolio CI